Cargando…
Formulation and in-vivo Evaluation of Novel Topical Gel of Lopinavir for Targeting HIV
BACKGROUND: Lopinavir is a specific reversible inhibitor of the enzyme HIV protease with mean oral bioavailability of less than 20% due to extensive hepatic metabolism by cytochrome P450 3A4. The reported half-life of Lopinavir is 5-6 hours and the maximum recommended daily dose is 400 mg/day. All t...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bentham Science Publishers
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416462/ https://www.ncbi.nlm.nih.gov/pubmed/30246641 http://dx.doi.org/10.2174/1570162X16666180924101650 |